Phio Pharmaceuticals Begins Commercial-Scale cGMP Manufacturing of PH-762
PHIO•Phio Pharmaceuticals has initiated first commercial-scale cGMP production of its lead siRNA drug PH-762 at Nitto Denko Avecia to support its next clinical trial phase. This batch follows completion of the Phase 1b dose-escalation study targeting cutaneous carcinomas and prepares for intratumoral program advancement.
1. Commercial-Scale cGMP Production Initiated
Phio has commenced the manufacture of its first commercial-scale cGMP batch of PH-762 at Nitto Denko Avecia’s Pennsylvania facility, marking a critical manufacturing milestone for its lead INTASYL-based compound.
2. Support for Upcoming Clinical Trial
The newly produced drug substance will supply the next phase of the intratumoral clinical program following completion of the Phase 1b dose-escalation study in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma patients.
3. Strategic Partnership with Nitto Denko Avecia
Under a June 2025 service agreement, Nitto Denko Avecia has completed analytical development, method validation and trial-scale manufacturing, positioning it as the primary cGMP provider for PH-762’s advancement.
